Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | CCR8 | P51685 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | PRNP | P04156 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | NQO2 | P16083 | 2/20 | 0.32 |
| ▸ | NCK1 | P16333 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31627462 | 0.80 | CCR1 (0.43) | CCR1CCR5CCR8CYP1A2CYP2A6 | |
| SCHEMBL20660798 | 0.78 | BACE1 (0.33) | CYP1A2CYP2A6BACE1MAPTRXFP1 | |
| SCHEMBL9088995 | 0.77 | CCR1 (0.41) | CCR1CCR5CCR8CYP1A2CYP2A6 | |
| SCHEMBL17582675 | 0.74 | PRNP (0.44) | CCR1CCR5CCR8CYP1A2CYP2A6 | |
| SCHEMBL7264434 | 0.73 | NQO2 (0.44) | CCR1CCR5CCR8CYP2A6PRNP | |
| SCHEMBL20660923 | 0.73 | BACE1 (0.38) | BACE1 | |
| SCHEMBL30908523 | 0.72 | POLB (0.37) | LMNABACE1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL15448465 | 0.72 | POLB (0.37) | LMNABACE1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL31219687 | 0.72 | ALDH1A1 (0.36) | CCR1CCR5CCR8PRNPNPSR1 | |
| SCHEMBL3927988 | 0.72 | LMNA (0.36) | CCR1CCR5CCR8CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| WO-2009009633-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |
| US-5491126-A | BENZOTRIAZINE DERIVATIVES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| US-5389600-A | A phenyl quinoxaline or benzotriazine antigrowth agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| EP-0559843-B1 | SUBSTITUTED N-HETEROBICYCLIC HERBICIDES | DU PONT (US) | 1994-09-14 | — | — | EP | disclosed |
| EP-0559843-A1 | SUBSTITUTED N-HETEROBICYCLIC HERBICIDES. | DU PONT (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009578-A1 | SUBSTITUTED FUSED HETEROCYCLIC HERBICIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5110347-A | Pre- and postemergence; quinoxaline derivatives | E. I DU PONT DE NEMOURS AND COMPANY (US) | 1992-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018163-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | CNR1, CNR2, PMP22 | CCR1 736/4885CCR5 1343/4885CCR8 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.